Convulsant agent pentylenetetrazol does not alter the structural and dynamical properties of dipalmitoylphosphatidylcholine model membranes

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 2, 2011, Pages 379-386

  Turker, Sevgi ^a   Wassall, Stephen ^b   Stillwell, William ^b   Severcan, Feride ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b INDIANA UNIVERSITY   (United States)

Author keywords

DPPC; DSC; ESR; FTIR; Membrane lipids; PTZ; Steady state fluorescence spectroscopy

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; MEMBRANE LIPID; MEMBRANE PROTEIN; PENTETRAZOLE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; INFRARED SPECTROSCOPY; LIPID VESICLE; MEMBRANE MODEL; NERVE FIBER; PRIORITY JOURNAL; PROTEIN STRUCTURE; SPECTROSCOPY; STEADY STATE FLUORESCENCE SPECTROSCOPY;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; CALORIMETRY, DIFFERENTIAL SCANNING; CONVULSANTS; ELECTRON SPIN RESONANCE SPECTROSCOPY; MEMBRANE LIPIDS; PENTYLENETETRAZOLE; SOLUBILITY; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMODYNAMICS;

EID: 78650196402     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.002     Document Type: Article

References (69)

1. Delorenzo R.J., Sun D.A., Deshpande L.S. Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. Pharmacol. Ther. 2005, 105:229-266.
2. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 1994, 14:3413-3425.
3. Patel M. Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures. Free Radic. Biol. Med. 2004, 3:1951-1962.
4. Fisher R.S. Animal models of the epilepsies. Brain Res. Rev. 1989, 14:245-278.
5. Bloms P., MuBhoff U., Madeja M., Müsch-Nittel K., Kuhlmann D., Spencer F., Speckmann E.J. Suppression of a ligand operated membrane currents by the epileptogenic agent pentylenetetrazol in oocytes of Xenopus laevis after injection of rat brain RNA. Neurosci. Lett. 1992, 147:155-158.
6. Bloms-Funke P., Madeja M., MuBhoff M., Speckmann E.J. Effects of pentylenetetrazol on GABA receptors expressed in oocytes of Xenopus laevis: extra- and intracellular sites of action. Neurosci. Lett. 1996, 205:115-118.
7. Hartung K., Hermann A. Differential effects of pentylenetetrazole on ion currents of Aplysia neurones. Brain Res. 1987, 419:55-64.
8. Onozuka M., Watanabe K. Intracellularly applied anti-P70 antibody blocks the induction of abnormal membrane properties by pentylenetetrazole in identified Euhadra neurons. Brain Res. 1996, 716:187-191.
9. Sechi G.P., Rosati G., Deiana G.A., Petruzzi V., Deriu F., De Riu P.L., Correddu P. Short communication, co-variation of free aminoacids in brain interstitial fluid during pentylenetetrazole-induced convulsive status epilepticus. Brain Res. 1997, 764:230-236.
10. Sejima H., Ito M., Kishi K., Tsuda H., Shiraiski H. Regional excitatory and inhibitory amino acid concentrations in pentylenetetrazol kindling and kindled rat brain. Brain Dev. 1997, 19:171-175.
11. Madeja M., Stocker M., MuBhoff U., Pongs O., Speckmann E.J. Potassium currents in epilepsy: effects of the epileptogenic agent pentylenetetrazol on a cloned potassium channel. Brain Res. 1994, 656:287-294.
12. Ramanjaneyulu R., Ticku M. Interactions of pentamethylene-tetrazole and tetrazole analogues with the picrotoxin site of the benzodiazepine-GABA receptor-ionophore complex. Eur. J. Pharm. 1984, 98:337-345.
13. Rocha L., Ackermann R.F., Engel J. Chronic and single administration of pentylenetetrazol modifies benzodiazepine receptor binding: an autoradiography study. Epilepsy Res. 1996, 24:65-72.
14. A receptor subunit mRNAs in the septum of rats subjected to pentylenetetrazol-induced kindling. Mol. Brain Res. 1999, 70:1-8.
15. Ekonomou A., Smith A., Angelatou F. Changes in AMPA receptor binding and subunit messenger RNA expression in hippocampus and cortex in the pentylenetetrazole-induced kindling model of epilepsy. Mol. Brain Res. 2001, 95:27-35.
16. Madeja M., MuBhoff U., Lorra C., Pongs O., Speckmann E.J. Mechanism of action of the epileptogenic drug pentylenetetrazol on a cloned neuronal potassium channel. Brain Res. 1996, 722:59-70.
17. Altrup U., Hader M., Caceres J.L.H., Malcharek S., Meyer M., Galla H. Epileptogenic drugs in a nervous system: electrophysiological effects and incorporation into a phospholipid layer. Brain Res. 2006, 1122:65-77.
18. Chalazonitis N., Boisson M. Abnormal Neuronal Discharges 1978, Raven Press, New York.
19. Gross G.J., Woodbury D.M. Effects of pentylenetetrazol on ion transport in the isolated to bladder. J. Pharm. Exp. Ther. 1972, 181:257-272.
20. Woodbury D.M. Convulsant Drugs: Mechanism of Action. Advances in Neurology 1980, Raven Press, New York, pp. 249-303.
21. + pump by the epileptogenic pentylenetetrazole. Pflügers Arch. Eur. J. Physiol. 1998, 437:79-85.
22. Hauser H., Poupart G. The Structure of Biological Membranes 1992, 3-71. CRC Press, Boca Raton, FL. P.L. Yeagle (Ed.).
23. Severcan F., Sahin I., Kazanci{dotless} N. Melatonin strongly interacts with zwitterionic model membranes-evidence from Fourier transform infrared spectroscopy and differential scanning calorimetry. Biochim. Biophys. Acta 2005, 1668:215-222.
24. Korkmaz F., Kirbiyik H., Severcan F. Concentration dependent different action of progesterone on the order, dynamics and hydration states of the head group of dipalmitoyl-phosphatidylcholinemembrane. Spectrosc. Int. J. 2005, 19:213-219.
25. Huang J., Buboltz J.T., Feigenson G.W. Maximum solubility of cholesterol in phosphatidylcholine and phosphatidylethanolamine bilayers. Biochim. Biophys. Acta 1999, 1417:89-100.
26. Bhattacharya S., Dileep P.V. Membrane-forming properties of cationic lipids bearing oxyethylene-based linkages. J. Phys. Chem. B 2003, 107:3719-3725.
27. Korkmaz F., Severcan F. Effect of progesterone DPPC membrane: evidence for lateral phase separation and inverse action in lipid dynamics. Arch. Biochem. Biophys. 2005, 440:141-147.
28. Sade A., Banerjee S., Severcan F. Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles. J. Liposome Res. 2009, 1-10.
29. Wassall S.R, Stillwell W. Interactions of retinoids with phospholipid-membranes-electron spin resonance spectroscopy. Methods Enzymol. 1990, 189:383-394.
30. Lakowicz J.R. Principles of Fluorescence Spectroscopy 1999, Kluwer Plenum Press, NY.
31. Baber J., Ellena J.F., Cafiso D.S. Distribution of general-anestheti{dotless}cs in phospholipid-bilayers determined using H-2 NMR and H-1-H-1 Noe spectroscopy. Biochemistry 1995, 19:6533-6539.
32. Cui F., Qin L., Zhang G., Liu Q., Yao X., Lei B. Interaction of anthracycline disaccharide with human serum albumin: Investigation by fluoresence spectroscopic technique and modeling studies. J. Pharm. Biomed. Anal. 2008, 48:1029-1036.
33. Merck Index 1983, Merck, Rahmay, NJ. Tenth edn.
34. Mora P.C., Cirri M., Mura P. Differential scanning calorimetry as a screening technique in compatibility studies of DHEA extended release formulations. J. Pharm. Biomed. Anal. 2006, 42:3-10.
35. Goldstein D.B. The effects of drugs on membrane fluidity. Annu. Rev. Pharmacol. Toxicol. 1984, 24:43-64.
36. Hendrich A.B., Michalak K., Wesolowska O. Phase separation is induced by phenothiazine derivatives in phospholipid/sphingomyelin/cholesterol mixtures containing low levels of cholesterol and sphingomyelin. Biophys. Chem. 2007, 130:32-40.
37. 3)F], M=Fe(II) and Co(II): solvothermal synthesis, crystal structures, thermal, spectroscopic, and magnetic properties. J. Solid State Chem. 2005, 178:3554-3562.
38. 31P spectroscopies and conformational analysis. Biochim. Biophys. Acta 2008, 1778:2535-2543.
39. Crupi V., Majolino D., Mondello M.R., Migliardo P., Venuti V. FTIR spectroscopy: a powerful tool in pharmacology. J. Pharm. Biomed. Anal. 2002, 29:1149-1152.
40. Liu K.Z., Schultz C.P., Johnston J.B., Beck F.W., Al-katib A.M., Mohammad R.M., Mantsch H.H. Infrared spectroscopic study of bryostatin I-induced membrane alterations in a B-CLL cell line. Leukemia 1999, 13:1273-1280.
41. +2 on phospholipid model membranes: an FTIR study. Chem. Phys. Lipids 2003, 123:165-176.
42. Moore D.J., Sills R.H., Mendelsohn R. Peroxidation of erythrocytes: FTIR spectroscopy studies of extracted lipids, isolated membranes, and intact cells. Biospectroscopy 1995, 1:133-140.
43. Severcan F., Cannistraro S. A spin label ESR and saturation transfer ESR study of alpha-tocopherol containing model membranes. Chem. Phys. Lipids 1990, 53:17-26.
44. Kazanci N., Severcan F. Concentration dependent different action of tamoxifen on membrane fluidity. Biosci. Rep. 2007, 27:247-255.
45. Kazanci{dotless} N., Toyran N., Haris P.I., Severcan F. Vitamin D2 at high and low concentrations exert opposing effects on molecular order and dynamics of dipalmitoyl phosphatidylcholine membranes. Spectroscopy 2001, 15:47-55.
46. Fa N., Ronkart S., Schanck A., Deleu M., Gaigneaux A., Goormaghtigh E., Minqeot-Leclercq M.P. Effect of the antibiotic azithromycin on thermotropic behavior of DOPC and DPPC bilayers. Chem. Phys. Lipids 2006, 144:108-116.
47. Moore D.J., Sills R.H., Patel N., Mendelsohn R. Conformational order of phospholipids incorporated into human erythrocytes: an FTIR spectroscopy study. Biochemistry 1996, 35:229-235.
48. Owen J.S., Bruckdorfer K., Day R.C., McIntyre N. Decreased erythrocyte membrane fluidity and altered lipid composition in human liver disease. J. Lipid Res. 1982, 23:124-132.
49. Chakravarti A., Slaugenhaupt S.A., Zubenko G.S. Inheritance pattern of platelet membrane fluidity in Alzheimer disease. Am. J. Hum. Genet. 1989, 44:799-805.
50. Kohlschütter A., Hübner C., Gärtner J., Reynolds J.F., Pullarkat R.K. Decreased membrane fluidity of lymphycotes from patients with juvenile neuronal ceroid-lipofuscinosis. Am. J. Med. Genet. 1987, 31:203-207.
51. Chen H.C., Mendelsohn R., Rerek M.E., Moore D.J. Fourier transform infrared spectroscopy and differential scanning calorimetry studies of fatty acid homogenous ceramide. Biochim. Biophys. Acta 2000, 1468:293-303.
52. Harrison J.E., Groundwater P.W., Brain K.R., Hadgraft J. Azone induced fluidity in human stratum corneum. A Fourier transform infrared spectroscopy investigation using the perdeuterated analogue. J. Control. Release 1996, 41:283-290.
53. Wassall S.R., McCabe R.C.Y., Ehringer D.W., Stillwell W. Effects of dietary fish oil on plasma high density lipoprotein. J. Biol. Chem. 1992, 267:8168-8174.
54. Severcan F., Cannistraro S. A spin label ESR and saturation transfer ESR study of a-tocopherol containing model membranes. Chem. Phys. Lipids 1990, 53:17-26.
55. Ondrias K. Use of electronspin resonance spectroscopy of spin labels for studying drug-induced membrane perturbation. J. Pharm. Biomed. Anal. 1989, 7:649-675.
56. Silva L., Coutinho A., Fedorov A., Prieto M. Nystatin-induced lipid vesicels permeabilization is strongly dependent on sterol structure. BBA-Biomembr. 2006, 1758:452-459.
57. Repakova J., Holopainen J.M., Morrow M.R., McDonald M.C., Capkova P., Vattulainen I. Influence of DPH on the structure and dynamics of a DPPC bilayer. Biophys. J. 2005, 88:3398-3410.
58. Ambrosini A., Bossi G., Dante S., Dubini B., Gobbi L., Leone L., Bossi M.G.P., Zolese G. Lipid-drug interaction: thermodynamic and structural effects of antimicotic fluconazole on DPPC liposomes. Chem. Phys. Lipids 1998, 95:37-47.
59. Casal H.L., Mantsch H.H., Hauser H. Infrared and 31 P-NMR studies of the interaction of Mg with phosphatidylserines: effect of hydrocarbon chain unsaturation. Biochim. Biophys. Acta 1989, 982:228-236.
60. Lombardi D., Cuenoud B., Kramer S.D. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?. Eur. J. Pharm. Sci. 2009, 38:533-547.
61. Klopman G., Zhu H. Recent methologies for the estimation of n-octanol/water partition coefficients and their use in the prediction of membrane transport properties of drugs. Mini Rev. Med. Chem. 2005, 5:127-133.
62. Boyar H., Severcan F. Oestrogen-phospholipid membrane interactions: an FTIR study. J. Mol. Struct. 1997, 408/409:269-272.
63. Lindberg A., Szalai Z., Pullerits T., Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007, 12:732-739.
64. Palmqvist M., Persson G., Lazer I., Rosenborg J., Larsson P., Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997, 10:2484-2489.
65. Kramer S.D., Braun A., Jakits-Deiser C., Wunderli-Allenspach H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propranolol to phosphatidylinositol containing liposomes. Pharm. Res. 1998, 15:739-744.
66. Fa N., Ronkart S., Schanck A., Deleu M., Gaigneaux A., Goonnaghtigh E., Mingeot-Leclercq M.P. Effect of the antibiotic azithromycin on thermotropic behavior of DOPC or DPPC bilayer. Chem. Phys. Lipids 2006, 144:108-116.
67. Wunderlich B., Leirer C., Idzko A.-L., Keyser U.F., Wixforth A., Myles V.M., Heimburg T., Schneider M.F. Phase-state dependent current fluctuations in pure lipid membranes. Biophys. J. 2009, 96:4592-4597.
68. Preetha A., Banerjee R., Huilgol N. Effect of temperature on surface properties of cervical tissue homogenate and organic phase monolayers. Colloid Surf. B 2007, 60:12-18.
69. Noda K., Takahashi K., Hibino H. Influence of phosphatidylcholine on the threshold dose of pentylenetetrazol for inducing seizure. Jpn. J. Psychopharm. 1988, 8:417-420.